)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
J. Molner
J. Molner (MOLNR) investor relations material
J. Molner H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
June 1 acquisition of an FDA-approved U.S. product portfolio expanded marketed products from 4 to 14 and added hospital and specialty pharmacy access; H1 includes one month of acquired sales.
Revenue rose to €1.965m from €551k; reported net profit was €1.442m, with €3.694m of non-recurring, non-cash negative goodwill income.
Financial highlights
H1 revenue €1.965m, up 256% YoY; generic-drug sales €1.555m, up 868%, while services revenue increased 5% to €410k.
Operating profit €1.559m versus a €1.508m loss; net profit €1.442m versus a €1.412m loss in H1 2025.
Raw materials, goods and services costs rose to €2.134m from €359k; other direct costs were €412k, including €206k of inventory write-offs.
Outlook and guidance
Rights to acquired products not currently marketed are expected to support launches in H1 2027; the development pipeline continued across formulation, stability and regulatory review.
Strategy targets niche, established medicines facing supply gaps, with moderate-volume production and flexible CMO partnerships to support supply continuity.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from J. Molner
- Product investment and relaunch work coincided with lower revenue, a wider loss and going-concern uncertainty.MOLNR
H2 2022 - Adjusted profitability rebounded, but liquidity pressures persist amid ongoing growth investments.MOLNRH2 2025
- Revenue dropped 58% as focus shifted to proprietary products and new U.S. launches.MOLNRH1 2025
- Revenue up 382% to €1.3M, but losses deepened; FDA approval and launches set for H2 2024.MOLNRH1 2024
- Revenue up 272% year-over-year, but net loss deepened amid expansion and investment.MOLNRH2 2024
Next J. Molner earnings date
H2 202630 Mar, 2027
J. Molner
Next J. Molner earnings date
H2 202630 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
J. Molner AS is a pharmaceutical company based in Tallinn, Estonia, specializing in the development and provision of generic drugs, particularly sterile injectable and dermatology formulations. The company serves pharmaceutical markets in the United States, Canada, and Europe. In addition to drug development, J. Molner AS offers analytical chemistry services, European market release support, and ongoing stability solutions for its clients. The company is headquartered in Tallinn, Estonia, and its shares are listed on the Nasdaq Tallinn.